GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoodRx investors under the federal securities laws.

ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – GDRX

A Wall Street analyst says this is a stock to buy, but traders are likely eyeing a different reason to get in on this stock.

Why GoodRx Holdings Stock Popped Today

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) from September 23, 2020 through November 16, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for GoodRx Holdings, Inc. investors under the federal securities laws.

GDRX FEB 9 DATE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against GoodRx Holdings, Inc.– GDRX

New York, New York--(Newsfile Corp. - January 22, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoodRx investors under the federal securities laws.To join the GoodRx class action, go...

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action - GDRX

NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the “Class Period”).

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against GoodRx Holdings, Inc. – GDRX

NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) from September 23, 2020 through November 16, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for GoodRx Holdings, Inc. investors under the federal securities laws.

GDRX FEB 9 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against GoodRx Holdings, Inc.– GDRX

Qiwi

QuantumScape

NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of QIWI, GDRX and QS

NEW YORK, Jan. 17, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoodRx investors under the federal securities laws.

ROSEN, A LEADING LAW FIRM, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – GDRX

New York, New York--(Newsfile Corp. - January 15, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoodRx investors under the federal securities laws.To join the GoodRx class action, go to...

ROSEN, A TRUSTED LAW FIRM, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - GDRX

Berry Petroleum Corp.

Northern Dynasty Minerals

NEW YORK, NY / ACCESSWIRE / January 15, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BRY, NAK and GDRX

Snowflake

A key metric for each company can signal investors that their growth stories are beginning to sour.

2 Recent IPOs to Watch in 2021

Amazon's foray into healthcare has investors thinking twice about this recent IPO, despite its strong growth numbers.

Is GoodRx Stock a Buy?

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021 lead...

ROSEN, LEADING AND RESPECTED INVESTOR COUNSEL, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action - GDRX

NEW YORK, NY / ACCESSWIRE / January 10, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NAK, QIWI and GDRX

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoodRx investors under the federal securities laws. To join the GoodRx class action, go to http://www.rosenlegal.com/cases-register-2011.html or call

ROSEN, A TOP RANKED LAW FIRM, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action – GDRX

LOS ANGELES, Jan. 8, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ: GDRX) for violations of §§10(b) and 20(a) of the Securities...

INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against GoodRx Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the “Class Period”).

GDRX DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against  GoodRx Holdings, Inc. – GDRX

PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- Berger Montague is investigating potential securities fraud claims against GoodRx Holdings, Inc. ("GoodRx" or the "Company") on behalf of investors who purchased GoodRx securities (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020...

GoodRx Stock: Berger Montague Investigates Alleged Securities Fraud Claims Against GoodRx Holdings, Inc. (NASDAQ: GDRX); Lead Plaintiff Deadline is February 16, 2021

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of GoodRx Holdings, Inc. (NASDAQ: GDRX) from September 23, 2020 through November 16, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for GoodRx Holdings, Inc. investors under the federal securities laws.

GDRX INVESTOR DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against GoodRx Holdings, Inc.– GDRX

NEW YORK, NY / ACCESSWIRE / January 6, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for NAK, GDRX and OTGLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK--(BUSINESS WIRE)---- $GDRX--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) securities during the period from September 23, 2020 through November 16, 2020 (the “Class Period”). Investors have until February 16, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The laws

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Has Been Filed Against GoodRx Holdings, Inc. and Encourages Investors to Contact the Firm Before February 16, 2021

New York, New York--(Newsfile Corp. - January 1, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 16, 2020, inclusive (the "Class Period"), of the important February 16, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoodRx investors under the federal securities laws.To join the GoodRx class action, go...

Rosen, A Globally Recognized Firm, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action - GDRX

Airbnb

American Well Corporation

BigCommerce Holdings, Inc.

DoorDash

Shift4 Payments

Lemonade

Paya Holdings

Vroom

Wish

The U.S. market for initial public offerings (IPOs) had a banner year in 2020 despite the pandemic — or perhaps because of it. Connected-commerce companies often led the way, frequently enjoying strong IPO pricing and even bigger first-day “pops” as investors realized that the digital shift created by the COVID-19 outbreak would likely never fully […]

The Connected Economy's 10 Biggest US IPOs Of 2020

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 to November 16, 2020, inclusive (the "Class Period") of the important February 16, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for GoodRx investors under the federal securities laws. To join the GoodRx class action, go to http://www.rosenlegal.com/cases-register-2011.html or call P

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds GoodRx Holdings, Inc. Investors of Important Deadline in Securities Class Action– GDRX

NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ: GDRX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired GoodRx securities between September 23, 2020 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/gdrx.      

GDRX Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies GoodRx Holdings, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 16, 2021

News for GoodRx Holdings Stock (GDRX)